15.89% v13,138,478 c.02400 f16,413,097 S@.015 3d prior

New Post Public Reply Private Reply Replies (0) Message Board
znewcar1
463
15.89% v13,138,478 c.02400 f16,413,097 S@.015 3d prior close.

Cerebain Biotech Corp. (CBBT) Stock Research Links

CBBT Board Company Profile Buy Rating Time & Sales News Filings Financials
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.

I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Next PR Unveils Cutting-Edge AI Optimization Solutions

Updated Category News Views 208

Next PR Launches Innovative AI Optimization Services Next PR, an award-winning public relations firm, has recently introduced its AI Optimization Services, aimed at helping brands maintain visibility and authority in today's AI-driven digital landscape. As companies strive to adapt to the ever-changing world of artificial intelligence and search engine results generated...

Continue Reading
Security and Vulnerability Management Market Set for Growth Surge

Updated Category News Views 144

Overview of the Security and Vulnerability Management Market The Security and Vulnerability Management Market is on an impressive trajectory, predicted to expand from USD 17.55 billion to USD 24.07 billion by 2030, reflecting significant growth propelled by rising global vulnerabilities. Market Growth Drivers Multiple factors are contributing to this market's growth....

Continue Reading
Bybit Unveils Groundbreaking MiCAR-Compliant Platform for Europe

Updated Category News Views 275

Introducing Bybit.eu: A New Era for European Crypto Users Bybit, a leader in the cryptocurrency exchange market and the world's second-largest by trading volume, is evolving by launching Bybit.eu. This fully MiCAR-compliant platform is crafted specifically for users across the European Economic Area (EEA). Bybit EU GmbH operates this platform as a licensed Crypto-Asset...

Continue Reading
Breakthrough Updates on NXP900 Clinical Development Journey

Updated Category News Views 128

Nuvectis Pharma Reports Significant NXP900 Findings Nuvectis Pharma, Inc. (NASDAQ: NVCT), known for its pioneering work in oncology, has shared key insights regarding NXP900 at a recent prestigious cancer research meeting. This innovative drug shows considerable promise in treating advanced cancers. Based on a Phase 1a dose-escalation study, NXP900 demonstrated strong...

Continue Reading
Elon Musk's Heartfelt Christmas Eve Adventure in Snowy Cold

Updated Category News Views 323

The Unexpected Christmas Quest of Elon Musk Christmas is a time when many cherish the joy of giving and receiving gifts. However, when you are someone like Elon Musk, a dynamic CEO known for pushing boundaries with Tesla and SpaceX, a forgotten gift can turn into an extraordinary adventure. Imagine waking on Christmas Eve only to realize that you forgot to buy your...

Continue Reading